TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01587729
Drug: Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
Study: NCT02947087
Drug: Prolastin-C
Normalized name: Prolastin-C
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
Study: NCT01075828
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
Study: NCT01736800
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
Study: NCT01736800
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
Study: NCT00171808
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03255694
Drug: PEG-somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Study: NCT05141240
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants who initiated CDK4/6i therapy
Study: NCT05141240
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants who initiated CDK4/6i therapy
Study: NCT00543114
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
Study: NCT00543114
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
Study: NCT00543114
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on Day 1 of each 28 day cycle
Study: NCT01327495
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ug/kg subcutaneous injection every 2 weeks
Study: NCT01786759
Drug: ClinOleic
Normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study: NCT01786759
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study: NCT02718430
Drug: VXM01
Normalized name: VXM01
DrugBank: VXM01 (DB17420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy targeting VEGFR2
Study: NCT00307684
Drug: double blind PR OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18, 36, 54,72 or 90 mg/day once daily for 4 weeks
Study: NCT00307684
Drug: open label PR OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
Study: NCT03795805
Drug: Intaarticular lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
Study: NCT02472314
Drug: 1.3% Liposomal Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local tissue infiltration of Liposomal Bupivacaine during surgery
Study: NCT01235273
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: growth hormone administration
Study: NCT00912262
Drug: Capsaicin Topical Liquid
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02478268
Drug: Hyperpolarized 129-Xenon gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Study: NCT02206152
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
Study: NCT00004286
Drug: immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067520
Drug: intrathecal hydromorphone (IT hydromorphone)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01393145
Drug: Combination Fluticasone /Formoterol 12/250 μg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
Study: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg od
Study: NCT00005108
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00720772
Drug: 25% intravenous (IV) sodium thiosulfate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 ml IV drip twice/week post hemodialysis
Study: NCT03386825
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)
Study: NCT00006011
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00006011
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02156726
Drug: low-dose FCR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FCR with attenuated dose of fludarabine and cyclophosphamide
Study: NCT02316327
Drug: gemcitabine, cisplatin and bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Therapeutic
Study: NCT01888900
Drug: DUAL
Normalized name: Opdualag
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Asunaprevir and Daclatsvir
Study: NCT01888900
Drug: QUAD
Normalized name: ProQuad
DrugBank: mu4-sulfido-quadro-tetracopper (DB03151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunaprevir, daclatsvir, peginterferon and ribavirin
Study: NCT01639560
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
Study: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg od
Study: NCT00973245
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg od
Study: NCT01001338
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol
Study: NCT01160289
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally, once daily for 12 weeks
Study: NCT02357225
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
Study: NCT01090180
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
Study: NCT01467882
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder and solution for solution for injection
Study: NCT02378389
Drug: Pyrotinib/Pyrotinib with Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
Study: NCT00430846
Drug: SGN-35
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
Study: NCT02875886
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined with amiloride
Study: NCT01015547
Drug: Infliximab plus methotrexate
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study: NCT01015547
Drug: Combination of DMARDs
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study: NCT04470973
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive cefuroxime as part of standard care.
Study: NCT00152932
Drug: Dorzolamide 2% drops
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04480138
Drug: Pegylated Interferon-α2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mcg/kg on day 1 and day 8 after safety evaluations.
Study: NCT00219102
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02774239
Drug: Human normal immunoglobulin G (IgG)
Normalized name: Human immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner.
Study: NCT00034060
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05596071
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
Study: NCT00570401
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00973245
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-adjusted warfarin based on target INR values
Study: NCT00525382
Drug: levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644291
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
Study: NCT04143958
Drug: agalsidase beta (GZ419828)
Normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
Study: NCT04143958
Drug: agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
Study: NCT00501839
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01452373
Drug: DHEA and Acolbifene
Normalized name: cytarabine and daunorubicin
DrugBank: Acolbifene (DB16080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
Study: NCT01896323
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-223 20 mg tablets
Study: NCT01896323
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 400 mg tablets
Study: NCT02786550
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
Study: NCT02686684
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01075802
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation
Study: NCT04458129
Drug: Treatment with polyethylene glycol (Macrogol 4000)
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
Study: NCT00958841
Drug: pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
Study: NCT00396019
Drug: PEG-Intron
Normalized name: Peg-Intron 50mcg Powder for Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01510613
Drug: Pomalidomide and Dexamethasone
Normalized name: Pomalidomide
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
Study: NCT03230864
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day, encapsulated tablets, orally
Study: NCT01240421
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
Study: NCT03230864
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4-6 mg/day, encapsulated tablets, orally
Study: NCT03230864
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-20 mg/day, encapsulated tablets, orally
Study: NCT01125514
Drug: Aliskiren 150 mg
Normalized name: aliskiren 150 MG
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg tablet
Study: NCT01125514
Drug: Furosemide 60 mg
Normalized name: furosemide 60 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 60 mg commercially-available tablets
Study: NCT01125514
Drug: Placebo for Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo for aliskiren 150 mg and 300 mg
Study: NCT01125514
Drug: Aliskiren 300 mg
Normalized name: aliskiren 300 MG
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300 mg tablet
Study: NCT00858364
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously once every 3 weeks
Study: NCT00003677
Drug: Dolastatin 10
Normalized name: Dolastatin 10
DrugBank: Dolastatin 10 (DB12730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus once every 21 days.
Study: NCT01768663
Drug: Lumacaftor
Normalized name: Lumacaftor
DrugBank: Lumacaftor (DB09280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, 200mg taken every 12 hours
Study: NCT01768663
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet, 250mg taken every 12 hours
Study: NCT01768663
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg taken every 12 hours
Study: NCT01768663
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg taken once daily
Study: NCT01768663
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg taken once daily
Study: NCT02244671
Drug: botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
Study: NCT03806543
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adult patients treated with intravenous vancomycin in intensive care unit
Study: NCT00418340
Drug: probiotic (bacterial/dietary supplement)
Normalized name: Rezyst Probiotic
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02984982
Drug: Alirocumab SAR236553
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT02984982
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02984982
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02984982
Drug: Bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02984982
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04716335
Drug: DMT
Normalized name: DMT
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT
Study: NCT04716335
Drug: Harmine
Normalized name: carminate
DrugBank: Harmine (DB07919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harmine
Study: NCT02601300
Drug: GED-0301
Normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00876577
Drug: Moxifloxacin (Avelox, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
Study: NCT02615002
Drug: Piromelatine
Normalized name: Piromelatine
DrugBank: Piromelatine (DB12288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02524639
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
Study: NCT01340677
Drug: Canagliflozin, 50 mg
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
Study: NCT01340677
Drug: Canagliflozin, 300 mg
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
Study: NCT01340677
Drug: Canagliflozin, 100 mg
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.